Sei Investments Co. lowered its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 3.8% during the second quarter, Holdings Channel reports. The fund owned 209,121 shares of the pharmaceutical company’s stock after selling 8,174 shares during the period. Sei Investments Co.’s holdings in GlaxoSmithKline PLC were worth $9,017,000 as of its most recent filing with the SEC.
Other hedge funds have also recently bought and sold shares of the company. Murphy Capital Management Inc. boosted its stake in GlaxoSmithKline PLC by 5.7% in the first quarter. Murphy Capital Management Inc. now owns 5,600 shares of the pharmaceutical company’s stock valued at $236,000 after buying an additional 300 shares during the last quarter. Bank of Montreal Can boosted its stake in GlaxoSmithKline PLC by 8.8% in the first quarter. Bank of Montreal Can now owns 128,238 shares of the pharmaceutical company’s stock valued at $5,407,000 after buying an additional 10,412 shares during the last quarter. Regentatlantic Capital LLC purchased a new stake in GlaxoSmithKline PLC during the first quarter valued at $268,000. Jacobs & Co. CA boosted its stake in GlaxoSmithKline PLC by 5.6% in the first quarter. Jacobs & Co. CA now owns 80,093 shares of the pharmaceutical company’s stock valued at $3,376,000 after buying an additional 4,270 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its stake in GlaxoSmithKline PLC by 6.7% in the first quarter. Capstone Asset Management Co. now owns 102,668 shares of the pharmaceutical company’s stock valued at $4,328,000 after buying an additional 6,420 shares during the last quarter. 8.96% of the stock is currently owned by institutional investors and hedge funds.
GlaxoSmithKline PLC (NYSE:GSK) opened at 38.79 on Friday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59. The company has a market capitalization of $94.80 billion, a PE ratio of 37.51 and a beta of 1.03. The company has a 50-day moving average price of $41.84 and a 200 day moving average price of $41.84.
GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.85 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be paid a $0.491 dividend. This represents a $1.96 annualized dividend and a yield of 5.06%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 197.00%.
TRADEMARK VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/12/sei-investments-co-lowers-position-in-glaxosmithkline-plc-nysegsk.html.
GSK has been the topic of several research reports. Zacks Investment Research cut GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, April 25th. TheStreet raised GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Finally, ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $46.00.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
What are top analysts saying about GlaxoSmithKline PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline PLC and related companies.